The Streptavidin coated AlphaPlex™ 645 (Samarium) Acceptor beads are used to capture a wide variety of biotinylated reagents, ranging from small nucleotides to very large proteins. To avoid steric hindrance, it is recommended to use biotin derivatives including an aliphatic spacer composed of at least six carbons.
For research use only; not for diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption & disposal requirements under European REACH regulations (EC 1907/2006).
Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
The Streptavidin coated AlphaPlex™ 645 (Samarium) Acceptor beads are used to capture a wide variety of biotinylated reagents, ranging from small nucleotides to very large proteins. To avoid steric hindrance, it is recommended to use biotin derivatives including an aliphatic spacer composed of at least six carbons. These beads can be used in conjunction with Alpha Donor beads to create no-wash assays for:
AlphaPlex Acceptor beads are intended to be used in multiplexing assays, in conjunction with AlphaLISA Acceptor beads and Alpha Donor beads. In a typical Alpha assay, 1 mg of Acceptor beads is sufficient to run 1,000-2,000 wells using a 50 μL reaction volume.
|Bead Type or Core Bead Type||AlphaPlex Samarium (645) Acceptor|
|Experimental Type||In vitro|
|Product Brand Name||AlphaPlex|
|Quantity in a Package Amount||1.0 per pack|
|Shipping Condition||Blue Ice|
|Unit Size||25 mg|
Anti-inflammatory monoclonal antibody drugs that specifically target TNFα, such as Humira®, have been highly successful in the market. As patents expire on these top-selling drugs, effort has been placed on developing biosimilars. Biosimilars differ from small molecule generic drugs in that their chemical structure does not have to be exactly the same as the patented drug. Therefore, the FDA has stringent requirements for proving that the biosimilars have the same efficacy and safety profile as the patented drug. Companies that develop biosimilars are tasked with proving that the biosimilar shows equivalent pharmacokinetics as the patented drug.
Proving “biosimilarity” involves comparing parameters such as overall exposure, absorption, half-life, and clearance time using patient samples. Sensitive, robust, and fast assays are needed to measure these parameters. Traditional methods for detecting and quantifying these drugs in patient samples include time-consuming, wash-based ELISA and MSD methods. In contrast, AlphaLISA allows for fast, no-wash, high-throughput detection and quantification of the drug of interest in a variety of sample matrices. Here, we demonstrate the application of AlphaLISA for detecting biosimilars targeting TNFα.